The radiopharmaceutical, I-131-MIP-1466, which is designed to deliver a therapeutic dose of radiation to metastatic prostate cancer, will enter a clinical trial to evaluate its efficacy and benefits for patients.

The team at Johns Hopkins In-Vivo Cellular and Molecular Imaging Center in Baltimore is using novel imaging tools to discover new early detection methods for cancers existing in cells, and study its prevention and elimination before spreading to other organs and tissues.

89Zr-desferrioxamine B-7E11 displays high tumor-to-background tissue contrast in immuno-PET and can be used as a tool to monitor and quantify with high specificity tumor response in prostate-specific membrane antigen (PSMA)-positive prostate cancer, according to research published in the October issue of the Journal of Nuclear Medicine.

LI-COR Biosciences has entered into a licensing agreement with Johns Hopkins University in Baltimore for compounds and imaging methods targeting prostate-specific membrane antigen (PSMA) developed in the laboratory of Martin G. Pomper, MD, a neuroradiologist at Johns Hopkins.